Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Cash from Operations (2018 - 2025)

Historic Cash from Operations for Neurogene (NGNE) over the last 6 years, with Q3 2025 value amounting to -$19.5 million.

  • Neurogene's Cash from Operations fell 2534.05% to -$19.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$77.2 million, marking a year-over-year decrease of 1029.72%. This contributed to the annual value of -$70.6 million for FY2024, which is 3730.12% down from last year.
  • Latest data reveals that Neurogene reported Cash from Operations of -$19.5 million as of Q3 2025, which was down 2534.05% from -$19.4 million recorded in Q2 2025.
  • Over the past 5 years, Neurogene's Cash from Operations peaked at -$9.3 million during Q2 2023, and registered a low of -$21.7 million during Q1 2024.
  • Moreover, its 3-year median value for Cash from Operations was -$16.9 million (2023), whereas its average is -$16.5 million.
  • In the last 5 years, Neurogene's Cash from Operations crashed by 7035.48% in 2024 and then soared by 414.75% in 2025.
  • Quarter analysis of 3 years shows Neurogene's Cash from Operations stood at -$16.9 million in 2023, then fell by 3.39% to -$17.5 million in 2024, then fell by 11.5% to -$19.5 million in 2025.
  • Its Cash from Operations stands at -$19.5 million for Q3 2025, versus -$19.4 million for Q2 2025 and -$20.8 million for Q1 2025.